提高青光眼患者依从性干预措施的研究进展被引量：4

下载PDF

导出

摘要青光眼是威胁人类健康的重要眼病,是导致视功能减退和致盲的主要原因之一,其造成的视功能损害往往是不可逆的.治疗青光眼方法主要包括药物、激光、手术三大类.每种治疗均以降低患者眼压为目的,但每种方法都不能确保眼压永久维持在正常范围内,治疗后仍需要患者定期复查或坚持用药,以确保视神经没有受到进一步损伤,有文献[1]报道青光眼患者依从性往往较差,分析其原因主要是由于医疗资源分配不均、健康教育工作开展滞后、医护与患者沟通不充分等问题所致,由此造成的患者失明已经成为青光眼致盲的主要原因.因此,国内外专家针对青光眼患者遵医行为开展一系列干预措施,以期最大限度的保护残存视功能.

作者刘华

机构地区天津医科大学眼科医院

出处《天津护理》 2015年第3期279-280,共2页 Tianjin Journal of Nursing

关键词青光眼依从性健康教育社会支持系统

分类号 R473.77 [医药卫生—护理学]

引文网络
相关文献

参考文献16

1Heather Waterman,Lisa Brunton,Cecilia Fenerty.Adherence to ocular hy- potens!ve therapy: patient health education needs and views on group edu- cation[J].Patient Prefer Adherence, 2013,7:55 - 63.
2Muir KW,Ventura A,Stinnett SS.The influence of health literacy level on an educational intervention to improve glaucoma medication adherence[J]. Patient Educ Couns,2012,87(2): 160-164.
3Liu Y, Mao W.Tafluprost once daily for treatment of elevated intraocular pressure in patients with open-angle glaucoma [J].Clin Ophthalmol,2013,7 (7): 14.
4Jean-Philippe N ,Christophe B ,Main B.Xal-Ease:impact of an ocular hy- potensive delivery device on ease of eyedrop administration, patient compli- ance,and satisfaction [J].European Journal of Ophthalmology,2009,19(6): 949-956.
5Zhang X,Cotch MF,Ryskulova A.Vision health disparities in the United States by race/ethnicity,education,and economic status: findings from two nationally representative survey [J ].Ophthalmol,2012,154(6):53-62.
6Kowal M,Choraglewicz T,Mietlicka K,et al.Obstacles to medication com- pliance for patients with glaucoma [J].Klin Oczna,2008,110 (10-12) : 347-351.
7Ashaye AO, Adeoye AO.Charactcristics of patients who dropout from a glau- coma clinlc[J]. J Glaucoma, 2008,17(3) : 227-232.
8Constance Okeke,Harry A,Henry D.Jampal.Interventions Improve Poor Ad- herence with Once Daily Glaucoma Medications in Electronically Monitored Patients[J] .Ophthalmology, 2009,116(12) : 2286 - 2293.
9陈立梅.恐惧诉求提高青光眼病人局部用药的依从性研究[J].护理研究（下旬版）,2012,26(1):205-207. 被引量：9
10Hoffeh Z,Fallon S,Wong BA.Glaucoma public service tors associated with follow-up of participants with risk factors forglaucoma [J]. Ophthalmology, 2011,118(7) : 1327-1333.

二级参考文献17

1Resnikoff S,Pascolini D,Etya'ale D,et al.Global data on visual impairment in the year 2002[J].Bulletin of the World Health Organization,2004,82:844-851.
2Bourne R.Worldwide Glaucoma through the Looking Glass[J].British Journal of Ophthalmology,2006,90(3):253-254.
3Foster P,Johnson G.Glaucoma in China:How big is the problem?[J].British Journal of Ophthalmology,2001,85(11):1277-1282.
4Bonomi L,Marchini G,Marraffa M,et al.The relationship between intraocular pressure and glaucoma in a defined population[J].Ophthalmologica,2000,215(1):34-38.
5Schwartz GF.Compliance and persistency in glaucoma follow-up treatment[J].Current Opinion in Ophthalmology,2005,16(2):114-121.
6Chawla A,McGalliard JN,Batterbury M.Use of eyedrops in glaucoma:How can we help to reduce non-compliance?[J].Acta Ophthalmologica Scandinavica,2007,85(4):464-464.
7Djafari F,Lesk MR,Harasymowycz PJ,et al.Determinants of adherence to glaucoma medical therapy in a long-term patient population[J].Journal of Glaucoma,2009,18(3):238-247.
8Ruiter R,Abraham C,Kok G.Scary warnings and rational precautions:A review of the psychology of fear appeals[J].Psychology & Health,2001,16(6):613-630.
9Witte K,Allen M.A meta-analysis of fear appeals:Implications for effective public health campaigns[J].Health Education & Behavior,2000,27(5):591-602.
10Lasagna L.Fault and default[J].New England Journal of Medicine,1973,289(5):267-268.